Literature DB >> 7636225

Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA4Ig.

D Yin1, C G Fathman.   

Abstract

It has been difficult to induce donor-specific transplantation tolerance in high responder Lewis rats. Results presented below demonstrate that amounts of pretransplant anti-CD4 sufficient to allow allograft tolerance in low responder strains (5 mg/kg x 4 days) did not prevent the acute rejection of ACI heart allografts in high responder Lewis recipients. Higher doses of pretransplant anti-CD4 (10 mg/kg, 15 mg/kg, and 20 mg/kg) given alone could delay but not prevent allograft rejection. Pretransplant anti-CD4 combined with anti-CD8, thymectomy, and total lymphoid irradiation all failed to produce tolerance to ACI heart allografts. However, a regimen of anti-CD4 combined with CTLA4Ig allowed indefinite survival of ACI heart allografts (mean survival time, > 100 day). Second-donor matched heart grafts were permanently accepted, and third-party heart grafts were permanently accepted, and third-party heart allografts were rejected by the tolerant recipients. These results suggest a new combination therapeutic strategy for clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636225

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Inhibition of corneal allograft reaction by CTLA4-Ig.

Authors:  F Hoffmann; E P Zhang; T Pohl; U Kunzendorf; J Wachtlin; S Bulfone-Paus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-08       Impact factor: 3.117

Review 3.  Antigen-presenting cell engineering. The molecular toolbox.

Authors:  M L Tykocinski; D R Kaplan; M E Medof
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

4.  Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.

Authors:  N R Srinivas; W C Shyu; R S Weiner; G Warner; C Comereski; L K Tay; D S Greene; R H Barbhaiya
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

Review 5.  [Regulation of T-cell activation by CD28 and CTLA-4].

Authors:  T Nagel; J R Kalden; B Manger
Journal:  Med Klin (Munich)       Date:  1998-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.